Eton Pharmaceuticals Inc [NASDAQ: ETON] stock went on an upward path that rose over 0.17% on Friday, amounting to a one-week price increase of more than 0.06%.
Over the last 12 months, ETON stock rose by 29.95%. The one-year Eton Pharmaceuticals Inc stock forecast points to a potential upside of 42.3. The average equity rating for ETON stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $464.21 million, with 26.82 million shares outstanding and 22.73 million shares in the current float. Compared to the average trading volume of 479.43K shares, ETON stock reached a trading volume of 160315 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Eton Pharmaceuticals Inc [ETON]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ETON shares is $30.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ETON stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Eton Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 23, 2025. While these analysts kept the previous recommendation, B. Riley Securities raised their target price to Buy. The new note on the price target was released on January 10, 2025, representing the official price target for Eton Pharmaceuticals Inc stock. Previously, the target price had yet another raise from $15 to $17, while H.C. Wainwright kept a Buy rating on ETON stock.
The Price to Book ratio for the last quarter was 19.37, with the Price to Cash per share for the same quarter was set at 0.95. Price to Free Cash Flow for ETON in the course of the last twelve months was 37.99 with Quick ratio for the last quarter at 1.16.
ETON Stock Performance Analysis:
Eton Pharmaceuticals Inc [ETON] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.06. With this latest performance, ETON shares gained by 22.25% in over the last four-week period, additionally plugging by 10.25% over the last 6 months – not to mention a rise of 29.95% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ETON stock in for the last two-week period is set at 61.58, with the RSI for the last a single of trading hit 0.70, and the three-weeks RSI is set at 0.80 for Eton Pharmaceuticals Inc [ETON]. The present Moving Average for the last 50 days of trading for this stock 15.33, while it was recorded at 17.28 for the last single week of trading, and 14.87 for the last 200 days.
Insight into Eton Pharmaceuticals Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Eton Pharmaceuticals Inc [ETON] shares currently have an operating margin of -0.15% and a Gross Margin at 59.41%. Eton Pharmaceuticals Inc’s Net Margin is presently recorded at -7.10%.
Eton Pharmaceuticals Inc (ETON) Capital Structure & Debt Analysis
According to recent financial data for Eton Pharmaceuticals Inc. ( ETON), the Return on Equity (ROE) stands at -22.06%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -6.18%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Eton Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -7.96%, showcasing its effectiveness in deploying capital for earnings.
Eton Pharmaceuticals Inc (ETON) Efficiency & Liquidity Metrics
Based on Eton Pharmaceuticals Inc’s (ETON) latest financial statements, the Debt-to-Equity Ratio is 1.28%, indicating its reliance on debt financing relative to shareholder equity.
Eton Pharmaceuticals Inc (ETON) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Eton Pharmaceuticals Inc. (ETON) effectively leverages its workforce, generating an average of -$133225.81 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.77% and a Quick Ratio of 1.16%, indicating strong ability to cover short-term liabilities.
ETON Stock EPS
With the latest financial reports released by the company, Eton Pharmaceuticals Inc posted 0.02/share EPS, while the average EPS was predicted by analysts to be reported at -0.01/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.03. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ETON.
Eton Pharmaceuticals Inc [ETON] Institutonal Ownership Details
There are presently around $62.47%, or 65.34%% of ETON stock, in the hands of institutional investors. The top three institutional holders of ETON stocks are: OPALEYE MANAGEMENT INC. with ownership of 2.4 million shares, which is approximately 9.2963%. VANGUARD GROUP INC, holding 1.03 million shares of the stock with an approximate value of $$3.38 million in ETON stocks shares; and VANGUARD GROUP INC, currently with $$3.1 million in ETON stock with ownership which is approximately 3.6515%.
